LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues

By LabMedica International staff writers
Posted on 13 May 2024
Image: The HSDFM generates an image where each pixel contains a spectral signature corresponding to tissue composition (Photo courtesy of Jeesong Hwang)
Image: The HSDFM generates an image where each pixel contains a spectral signature corresponding to tissue composition (Photo courtesy of Jeesong Hwang)

Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue. This procedure is typically advised for women with early-stage breast cancer or small tumors, as it conserves more of the breast tissue compared to a mastectomy. After undergoing BCS, it is critical to verify that all cancerous cells have been removed to decide if additional surgery is necessary. This verification involves a tumor margin assessment, which examines the edges of the excised tissue (tumor margins) to check for residual cancer cells. Conventionally, this assessment entails staining the tissue samples with dyes and inspecting them under a microscope to differentiate between healthy and cancer cells. However, new optical imaging techniques have emerged as quicker alternatives for conducting these assessments.

A group of researchers from the United States, including members from the National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA), has introduced hyperspectral dark-field microscopy (HSDFM) as an effective technique to swiftly and accurately distinguish between cancerous and healthy cells and identify various tumor subtypes in breast tissues post-lumpectomy. In HSDFM, tissue samples are exposed to multiple wavelengths of light, and the varying intensity of light scattered by cellular and molecular components is analyzed to create distinctive spectral signatures for each type of tissue. This technique generates two-dimensional images where each pixel holds spectral data across multiple wavelengths, enabling precise identification of tissue composition. This approach specifically tackles the limitations commonly faced in hyperspectral tumor margin imaging techniques, which typically depend on reflectance to collect spectral information from tissue samples.

Reflectance-based imaging techniques often struggle with issues like the uneven absorption of light by biological substances, such as oxyhemoglobin in blood, which can lead to inconsistent spectral signatures from different samples. In their study, the researchers examined HSDFM images of breast lumpectomy specimens from several patients. They employed two machine learning strategies to categorize the pixels by tissue type: a supervised method and an unsupervised method. The supervised method utilized was spectral angle mapping, which involves comparing the spectral signature of each pixel against known spectral signatures of different tumor subtypes and tissue types (like fat, connective tissue, and blood) previously identified via histopathological analysis.

For the unsupervised method, they applied the K-means clustering algorithm, which sorts pixels into clusters based on similarity in their spectral signatures, thereby aiding in the identification of tumor regions without needing prior spectral data or specific tissue type knowledge. The spectral signatures derived from both the supervised and unsupervised methods were similar and effectively pinpointed areas containing invasive ductal carcinoma—the most prevalent form of breast cancer, accounting for 75% of all cases—as well as invasive mucinous carcinoma, a less common type where cancer cells grow in mucus. The results indicate that the unsupervised approach is validated by the supervised method, suggesting that HSDFM imaging data could be instrumental in developing unsupervised algorithms for the quick and accurate detection of cancerous tissues, which is expected to improve post-surgical monitoring and treatment planning in BCS, enabling more timely interventions.

Related Links:
NIST

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more